Abbott India Ltd
Abbott India Limited, a publicly listed company, subsidiary of Abbott Laboratories is headquartered in Mumbai and enjoys strong brand equity in multiple therapeutic categories such as Women’s Health, Gastroenterology,
Neurology, Thyroid, Diabetes & Urology, Pain Management, Vitamins, Anti-Infectives and other therapy areas.
Neurology, Thyroid, Diabetes & Urology, Pain Management, Vitamins, Anti-Infectives and other therapy areas.
Abbott India is one of India’s fastest growing pharmaceutical companies. Abbott India’s success is driven by a combination of a highly competent and motivated commercial team, R&D backed products and aided by strong alliances and partnerships with suppliers and vendors. Abbott India employs over 2,600 people and reaches customers through a network of 35 distribution points, catering to over 4,500 stockists and 150,000 retail outlets. The Company has over 100 employees at a state of-the-art formulation plant at Verna, Goa. The manufacturing plant is designed to produce high volume and quality formulations using cost efficient processes and has well equipped laboratories and trained personnel to ensure compliance with international quality standards. Brufen', 'Digene', and 'Cremaffin', Duflac, Vertin are established brands of Abbott India Ltd. In 2010, Abbott acquired Solvay Pharmaceuticals and domestic formulations business of Piramal Healthcare Limited.
| Quarter ended |
Year to Date |
Year ended | |||||||
| 201406 (3) |
201306 (3) |
% Var | - | - |
201403 (15) |
201212 (12) |
% Var | ||
| Sales | 516.91 | 429.68 | 20.30 | NA | NA | NA | 2231.29 | 1613.09 | NA |
| Other Income | 9.60 | 6.72 | 42.86 | NA | NA | NA | 48.22 | 51.39 | NA |
| PBIDT | 79.69 | 49.19 | 62.00 | NA | NA | NA | 316.56 | 234.50 | NA |
| Interest | 0.01 | 0.03 | -66.67 | NA | NA | NA | 0.08 | 0.02 | NA |
| PBDT | 79.68 | 49.16 | 62.08 | NA | NA | NA | 316.48 | 234.48 | NA |
| Depreciation | 3.49 | 4.78 | -26.99 | NA | NA | NA | 21.93 | 19.49 | NA |
| PBT | 76.19 | 44.38 | 71.68 | NA | NA | NA | 294.55 | 214.99 | NA |
| TAX | 25.26 | 14.67 | 72.19 | NA | NA | NA | 96.10 | 70.29 | NA |
| PAT | 50.93 | 29.71 | 71.42 | NA | NA | NA | 198.45 | 144.70 | NA |
| Equity | 21.25 | 21.25 | 0.00 | NA | NA | NA | 21.25 | 21.25 | NA |
EXPECTING COMPANY TO POST 100 EPS FOR FULL YEAR . ONE CAN EXPECT 4500 RS IN NEXT ONE YEAR SO BUY ON EVERY DECLINE ONE SHOULD HAVE IN THEIR PORTIFOLIO
please include my name in your mailing list
ReplyDelete